SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-017921
Filing Date
2021-09-01
Accepted
2021-09-01 07:09:58
Documents
13
Period of Report
2021-08-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20210830.htm   iXBRL 8-K 44678
2 EX-99.1 ex991oxford-foghornxsecond.htm EX-99.1 27605
  Complete submission text file 0001628280-21-017921.txt   219390

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20210830.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20210830_lab.xml EX-101.LAB 24844
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20210830_pre.xml EX-101.PRE 13045
6 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20210830_htm.xml XML 11443
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 211228745
SIC: 2834 Pharmaceutical Preparations